Medical Condition News

RSS

Treatment of Type 1 diabetes patients with DiaPep277- may have several medical benefits

The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.

23 Nov 2011

FDA approves Medtronic's iPro2 Professional continuous glucose monitoring system

Medtronic, Inc. today announced the Food and Drug Administration (FDA) approval of iPro2, a next generation Professional continuous glucose monitoring (CGM) system and the latest in a series of recent diabetes technology approvals and innovations from the company.

From Medtronic 22 Nov 2011

Biochemists identify structure of hydroxyurea that specifically inhibits proteasome

As the "recycling plant" of the cell, the proteasome regulates vitally important functions. When it is inhibited, the cell chokes on its own waste. Cancer cells, in particular, are very sensitive because they need the proteasome for their uncontrolled growth. Biochemists at the Technische Universitaet Muenchen (TUM) have now identified the lead structure of a new class of drugs that attacks the proteasome in an unusual way. New medication could be developed on the basis of this previously unknown binding mechanism.

22 Nov 2011

Arginine may reactivate T-cells in patients with glioblastoma

In many cases, tumors suppress a patient's immune system in a way that keeps the cancer safe from immune system attack. This is particularly true for patients with glioblastoma, a primary brain tumor that carries a prognosis of only 12-15 months survival after diagnosis.

22 Nov 2011

IsoRay receives Washington State approval for GliaSite system to treat brain cancer

IsoRay, Inc. announced today it has received final approval from the State of Washington Department of Health to manufacture its GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer. In conjunction with the previously announced FDA clearance, the Washington State approval represents IsoRay's final regulatory hurdle to commence the sale of its GliaSite brain cancer treatment in the United States.

22 Nov 2011

CWRU receives NHLBI grant to study sleep apnea as possible cause of AF

Case Western Reserve University School of Medicine has received a $3.8 million grant from the National Heart, Lung, and Blood Institute (NHLBI) to study sleep apnea as a possible cause of atrial fibrillation (AF), the most commonly diagnosed type of arrhythmia, or irregular heart rhythm.

22 Nov 2011

FDA accepts Regeneron's ARCALYST sBLA for review

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental Biologics License Application (sBLA) for ARCALYST Injection for Subcutaneous Use for the prevention of gout flares in patients initiating uric acid-lowering therapy.

22 Nov 2011

Alzheimer’s disease progression and body weight may be linked: Study

There have been studies that show that people who are overweight in middle age are more likely to develop Alzheimer's disease decades later than people at normal weight. However some studies also show that people in the earliest stages of Alzheimer's disease are more likely to have a lower body mass index (BMI).

22 Nov 2011

Sore throat among young adults taking antibiotics for acne: Study

A new study reveals that young adults who take oral antibiotics for acne may be more likely to get sore throats. The reason behind this is unclear say researchers. However they add that long-term use of antibiotics might change the balance of bacteria in the throat. In principle, that could allow infection-causing strains to multiply.

22 Nov 2011

PAREXEL implements fMRI technology in early phase CNS drug development

PAREXEL International, a leading global biopharmaceutical services provider, today announced that it has enhanced its central nervous system (CNS) capabilities for clinical development through the implementation of functional magnetic resonance imaging (fMRI) technology in its Early Phase units.

From Parexel 22 Nov 2011

TRIGOcare, Systagenix partner to deliver wound care products

In a pressed economic climate, the estimated 3 million chronic wounds treated every year costs the German health care system several billion Euros, a situation fuelled by an annual prevalence of 650,000 new patients. This creates an immense cost pressure on everyone involved in wound care, in a market already characterised by tough competition, ever changing political framework and an expectation of innovation and improved quality of care.

22 Nov 2011

Researchers discover molecular sensor that detects wound-induced hydrogen peroxide

Hydrogen peroxide isn't just that bottled colorless liquid in the back of the medicine cabinet that's used occasionally for cleaning scraped knees and cut fingers. It's also a natural chemical in the body that rallies at wound sites, jump-starting immune cells into a series of events. A burst of hydrogen peroxide causes neutrophils, the immune system's first responders, to rush to the wound to fight microorganisms, remove damaged tissue and then start the inflammation process.

22 Nov 2011

Study: Vaccine development efforts currently focus on incidence rather than mortality rates

Drug companies currently developing therapeutic cancer vaccines may be determining the cancers they target based on the number of annual cases, not the number of deaths they cause.

22 Nov 2011

Police officers no more likely than general population to suffer from PSTD

Although police officers are at a high risk of experiencing traumatic events (TE) in their work, they are no more likely than the general population to suffer from post-traumatic stress disorder.

22 Nov 2011

Tips for people with addiction to help prevent relapse

The holiday season can be an especially trying time of year for those in recovery. The California Association of Marriage and Family Therapists offers tips for those suffering with addiction to help prevent relapse.

22 Nov 2011

Diaverum signs joint venture agreement with Nazer Group

November 2011: Diaverum, one of the world´s largest independent renal care providers, has signed a joint venture agreement with Nazer Group, a Saudi Arabian Holding Company with major investments in the medical sector including Bupa Arabia.

22 Nov 2011

New device safe, more effective for patients with chronic neurological conditions

Functional electrical stimulation (FES) was developed to help return lost function to patients with upper and lower extremity injuries and spinal cord injuries, among other applications. However, the devices, which work by stimulating neuronal activity in nerve-damaged patients, have a potential shortcoming in that the electrical currents needed for the treatment to work can also send errant signals to surrounding nerves, resulting in painful side effects.

22 Nov 2011

New way to exploit expression of BRAF by papillary carcinomas for therapeutic purposes

Papillary carcinoma is the most common form of thyroid cancer. Approximately one quarter of these carcinomas have mutations in the BRAF gene. The prevalence of such mutations is even greater in high-grade carcinomas, particularly those that are refractory to standard treatment, which is radioactive iodine.

22 Nov 2011

Non-alcoholic fatty liver disease does not appear to affect survival

Non-alcoholic fatty liver disease (NAFLD) is a common condition associated with obesity and heart disease long thought to undermine health and longevity. But a new study by Johns Hopkins researchers suggests the condition does not affect survival.

22 Nov 2011

New system could measure mechanical properties of living cells

Researchers are making progress in developing a system that measures the mechanical properties of living cells, a technology that could be used to diagnose human disease and better understand biological processes.

22 Nov 2011

Medical Condition News

Treatment of Type 1 diabetes patients with DiaPep277- may have several medical benefits

FDA approves Medtronic's iPro2 Professional continuous glucose monitoring system

Biochemists identify structure of hydroxyurea that specifically inhibits proteasome

Arginine may reactivate T-cells in patients with glioblastoma

IsoRay receives Washington State approval for GliaSite system to treat brain cancer

CWRU receives NHLBI grant to study sleep apnea as possible cause of AF

FDA accepts Regeneron's ARCALYST sBLA for review

Alzheimer’s disease progression and body weight may be linked: Study

Sore throat among young adults taking antibiotics for acne: Study

PAREXEL implements fMRI technology in early phase CNS drug development

TRIGOcare, Systagenix partner to deliver wound care products

Researchers discover molecular sensor that detects wound-induced hydrogen peroxide

Study: Vaccine development efforts currently focus on incidence rather than mortality rates

Police officers no more likely than general population to suffer from PSTD

Tips for people with addiction to help prevent relapse

Diaverum signs joint venture agreement with Nazer Group

New device safe, more effective for patients with chronic neurological conditions

New way to exploit expression of BRAF by papillary carcinomas for therapeutic purposes

Non-alcoholic fatty liver disease does not appear to affect survival

New system could measure mechanical properties of living cells

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News